A high-throughput screening platform for activating silent bacterial gene clusters and discovering cryptic metabolites

Background

The field of natural product discovery, particularly from bacterial sources, has long been a cornerstone of pharmaceutical innovation, yielding the majority of clinically used antibiotics and many anticancer agents. Advances in genome sequencing have revealed that bacteria, especially prolific producers like actinomycetes, possess a vast array of biosynthetic gene clusters capable of generating diverse small molecules. However, it has become evident that standard laboratory cultivation conditions only allow access to a small fraction—estimated at about 10%—of this chemical diversity. The remaining gene clusters are “silent” or inactive, meaning they do not express their biosynthetic potential under typical growth conditions. Unlocking these silent gene clusters is crucial for discovering new therapeutics, especially in the face of rising antibiotic resistance and the urgent need for novel bioactive compounds.

Despite the promise held by these silent gene clusters, current approaches to activating and studying them face significant limitations. Traditional methods rely on random mutagenesis, co-cultivation, or environmental manipulation, but these strategies are often inefficient, labor-intensive, and lack specificity. A major bottleneck is the absence of knowledge about the natural signals or small-molecule elicitors that can trigger expression of these clusters. As a result, the majority of cryptic metabolites remain inaccessible, and the full biosynthetic potential of bacteria is left untapped. Furthermore, without reliable high-throughput methods to systematically identify activators, researchers are unable to efficiently screen large libraries of potential elicitors or link gene cluster activation to metabolite production, hindering both basic research and drug discovery efforts.

Technology

This technology is a comprehensive platform designed to systematically activate silent biosynthetic gene clusters in bacteria, enabling the discovery of previously inaccessible small molecules with potential therapeutic value. The process begins by genetically engineering bacteria to insert a reporter gene—such as lacZ, GFP, or the lux operon—directly into a silent or lowly-expressed gene cluster. These modified bacteria are then exposed to a variety of chemical modulators, including sub-inhibitory antibiotics and other small molecules, in a high-throughput screening format. Activation of the gene cluster is detected by monitoring reporter gene expression, which signals the production of cryptic metabolites. Once activation is confirmed, these metabolites are extracted and characterized using advanced analytical techniques like high-performance liquid chromatography and mass spectrometry. The platform also includes a ready-to-use kit containing the engineered bacteria, streamlining the screening process for researchers.

What sets this technology apart is its ability to unlock the vast, untapped biosynthetic potential of bacteria, which traditional methods have failed to access—often reaching only about 10% of the small molecule repertoire. By integrating genetic engineering, high-throughput screening, and robust analytical workflows, the platform enables rapid identification of both elicitors and the resulting novel metabolites. Its versatility allows application to any bacterial gene cluster and adapts to a wide range of chemical stimuli. The discovery of acybolins—a new class of cryptic metabolites featuring unique structural motifs—demonstrates the platform’s effectiveness in revealing structurally and functionally novel compounds. This approach not only accelerates natural product discovery but also provides a scalable and reproducible method for generating new leads in antibiotic and drug development, addressing a critical bottleneck in pharmaceutical innovation.

Benefits

• Enables high-throughput identification of small molecule elicitors that activate silent bacterial biosynthetic gene clusters.
• Facilitates discovery and production of novel cryptic metabolites with potential therapeutic applications.
• Uses genetically engineered bacteria with reporter genes for sensitive and specific detection of gene cluster activation.
• Applicable to diverse bacterial species and gene clusters, allowing broad screening versatility.
• Incorporates automated, scalable screening methods suitable for large compound libraries.
• Provides a kit to streamline and standardize the screening process for activating silent gene clusters.
• Supports structural characterization of newly discovered metabolites using advanced analytical techniques.
• Unlocks previously inaccessible bacterial natural products, expanding the repertoire of bioactive compounds for drug discovery.

Applications

• Novel antibiotic discovery
• Anticancer drug development
• Natural product screening kits
• Biotechnology compound libraries
• Microbial metabolite production optimization

Additional info

This platform employs high-throughput screening to activate silent bacterial biosynthetic gene clusters. By integrating reporter genes into these clusters, researchers identify chemical elicitors, including sub-inhibitory antibiotics, that trigger metabolite expression. Subsequent analytical characterization via HPLC and mass spectrometry facilitates the discovery of acybolins. These metabolites feature fused cyclohexene and six-membered ring systems with lactone groups and variable acyl chains, providing a robust pathway for drug discovery.